Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
McNamara PJ, Chock VY, Rahde-Bischoff A, Gabrio J, Johnson KJ, Harmon HM, Montoya-Williams D, Colaizy TT, Katheria AC, Ines F, Sorrells K, Battersby C, Levy PT, Rysavy MA, Bhombal S, Laughon MM, Carper B, Hintz SR, Das A, Bell EF. Evaluating the efficacy and safety of milrinone for prevention of post-patent ductus arteriosus closure syndrome (the MIDAS trial) in extremely preterm infants: a multicentre, double-masked, randomised, placebo-controlled trial. BMJ Open. 2025 Aug 26; 15(8):e105018.
-
Ohls RK, Das A, Tan S, Lowe JR, Schibler K, Beauman SS, Bell EF, Laptook AR, Baserga M, Patel RM, Carlton DP, Flibotte J, Grisby C, Higgins RD, Shankaran S, Watterberg K, Hibbs AM, Carlo WA, Colaizy TT, Van Meurs KP, Kicklighter SD, Moore R, Sollinger C, Chalak LF, Ghavam S, Poindexter BB, Tyson JE, Cotten CM, Baack ML, Fathi O, DeMauro SB, Laughon MM, Reynolds AM, Duncan AF, Winter S, Wilson-Costello DE, Peralta-Carcelen M, Vohr BR, Harmon HM, Hintz SR, Cavanaugh B, Heyne RJ, Merhar S, Mosquera R, Sewell E, Malcolm WF, Richards LA, Benninger KL, Trembath A. Darbepoetin, Red Cell Mass, and Neuroprotection in Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2025 Aug 01; 179(8):836-845.
-
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fern?ndez Land? L, Denning M, Ludwig L, Chen Y. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Sep 18; 393(11):1065-1076.
-
Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, Weir MR, Ofili EO, Mehra R, Luther JM, Cohen DL, Sarraju A, Wilkinson MJ, Flack JM, Rodman D, Nissen SE. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025 May 08; 392(18):1813-1823.
-
Papapostolou S, Iles L, O'Brien J, Gutman SJ, Ellims A, Hare J, Stub D, Moir S, Taylor AJ. The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JACC Heart Fail. 2025 Jul; 13(7):102415.
-
Muduli S, Sarkar S, Pal RK, Ghosh S, Alam SM, Saha S, Naskar S, Roy S, Saha A, Halder I, Ghosh P, Shaikh AR, Koley M, Mukherjee SK. Homeopathic Treatment of Chronic Low-Back Pain: A Double-Blind, Randomized, Placebo-Controlled Trial. J Integr Complement Med. 2025 Jun; 31(6):565-576.
-
Bishop JR, Zhou C, Gaedigk A, Krone B, Kittles R, Cook EH, Newcorn JH, Stein MA. Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study. J Child Adolesc Psychopharmacol. 2024 12; 34(10):458-469.
-
Rana A, Bhattacharya P, Ganguly S, Saha S, Naskar S, Ghosh S, Shaikh AR, Koley M, Saha S, Mukherjee SK. Individualized Homeopathic Medicinal Products in the Treatment of Post-COVID-19 Conditions: A Double-Blind, Randomized, Placebo-Controlled, Feasibility Trial. J Integr Complement Med. 2025 Jan; 31(1):64-74.
-
Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
Farchione TJ, Long LJ, Gallagher MW, Spencer-Laitt D, Torre M, Woodard LS, Curreri AJ, Brown B, Ross M, Barlow DH. Results from a randomized controlled trial of zonisamide in the treatment of alcohol use disorder. J Psychiatr Res. 2024 Nov; 179:182-190.